169 related articles for article (PubMed ID: 38302415)
1. Prognostic and predictive value of angiogenesis-associated serum proteins for immunotherapy in esophageal cancer.
Gao M; Wu X; Jiao X; Hu Y; Wang Y; Zhuo N; Dong F; Wang Y; Wang F; Cao Y; Liu C; Li J; Shen L; Zhang H; Lu Z
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38302415
[TBL] [Abstract][Full Text] [Related]
2. Resistance to immune checkpoint inhibitors in advanced lung cancer: Clinical characteristics, potential prognostic factors and next strategy.
Zhou J; Lu X; Zhu H; Ding N; Zhang Y; Xu X; Gao L; Zhou J; Song Y; Hu J
Front Immunol; 2023; 14():1089026. PubMed ID: 36776868
[TBL] [Abstract][Full Text] [Related]
3. In-depth plasma proteomics reveals increase in circulating PD-1 during anti-PD-1 immunotherapy in patients with metastatic cutaneous melanoma.
Babačić H; Lehtiö J; Pico de Coaña Y; Pernemalm M; Eriksson H
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32457125
[TBL] [Abstract][Full Text] [Related]
4. Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer.
Jiang J; Jin Z; Zhang Y; Peng L; Zhang Y; Zhu Z; Wang Y; Tong D; Yang Y; Wang J; Yang Y; Xiao K
Front Immunol; 2021; 12():646874. PubMed ID: 33927719
[TBL] [Abstract][Full Text] [Related]
5. Potential predictive value of change in inflammatory cytokines levels subsequent to initiation of immune checkpoint inhibitor in patients with advanced non-small cell lung cancer.
Lim JU; Yoon HK
Cytokine; 2021 Feb; 138():155363. PubMed ID: 33264749
[TBL] [Abstract][Full Text] [Related]
6. Baseline Modified Glasgow Prognostic Score Associated with Survival in Metastatic Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors.
Brown JT; Liu Y; Shabto JM; Martini DJ; Ravindranathan D; Hitron EE; Russler GA; Caulfield S; Yantorni LB; Joshi SS; Kissick H; Ogan K; Harris WB; Carthon BC; Kucuk O; Master VA; Bilen MA
Oncologist; 2021 May; 26(5):397-405. PubMed ID: 33634507
[TBL] [Abstract][Full Text] [Related]
7. The Application of Combined Immune Checkpoint Inhibitor Modalities in Previously Treated Non-Small Cell Lung Cancer Patients and the Associations Thereof With the Lung Immune Prognostic Index.
Zhang T; Yang X; Zhao J; Xia L; Wang Q; Jin R; Zhou L; Zhang B; Zhao J; Li H; Li W; Xia Y
Front Oncol; 2021; 11():690093. PubMed ID: 34150659
[TBL] [Abstract][Full Text] [Related]
8. A mutation-based gene set predicts survival benefit after immunotherapy across multiple cancers and reveals the immune response landscape.
Long J; Wang D; Wang A; Chen P; Lin Y; Bian J; Yang X; Zheng M; Zhang H; Zheng Y; Sang X; Zhao H
Genome Med; 2022 Feb; 14(1):20. PubMed ID: 35197093
[TBL] [Abstract][Full Text] [Related]
9. Body Composition as an Independent Predictive and Prognostic Biomarker in Advanced Urothelial Carcinoma Patients Treated with Immune Checkpoint Inhibitors.
Martini DJ; Shabto JM; Goyal S; Liu Y; Olsen TA; Evans ST; Magod BL; Ravindranathan D; Brown JT; Yantorni L; Russler GA; Caulfield S; Goldman JM; Nazha B; Joshi SS; Kissick HT; Ogan KE; Harris WB; Kucuk O; Carthon BC; Master VA; Bilen MA
Oncologist; 2021 Dec; 26(12):1017-1025. PubMed ID: 34342095
[TBL] [Abstract][Full Text] [Related]
10. An antigen processing and presentation signature for prognostic evaluation and immunotherapy selection in advanced gastric cancer.
Wang KW; Wang MD; Li ZX; Hu BS; Wu JJ; Yuan ZD; Wu XL; Yuan QF; Yuan FL
Front Immunol; 2022; 13():992060. PubMed ID: 36311733
[TBL] [Abstract][Full Text] [Related]
11. Immune Checkpoint Inhibitors in Esophageal Cancers: are we Finally Finding the Right Path in the Mist?
Vivaldi C; Catanese S; Massa V; Pecora I; Salani F; Santi S; Lencioni M; Vasile E; Falcone A; Fornaro L
Int J Mol Sci; 2020 Feb; 21(5):. PubMed ID: 32121290
[TBL] [Abstract][Full Text] [Related]
12. Immune and genomic biomarkers of immunotherapy response in cancer of unknown primary.
Posner A; Sivakumaran T; Pattison A; Etemadmoghadam D; Thio N; Wood C; Fisher K; Webb S; DeFazio A; Wilcken N; Gao B; Karapetis CS; Singh M; Collins IM; Richardson G; Steer C; Warren M; Karanth N; Fellowes A; Fox SB; Hicks RJ; Schofield P; Bowtell D; Prall OWJ; Tothill RW; Mileshkin L
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36720497
[TBL] [Abstract][Full Text] [Related]
13. Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Shoji F; Takeoka H; Kozuma Y; Toyokawa G; Yamazaki K; Ichiki M; Takeo S
Lung Cancer; 2019 Oct; 136():45-51. PubMed ID: 31437663
[TBL] [Abstract][Full Text] [Related]
14. Prognostic and predictive impact of neutrophil-to-lymphocyte ratio and HLA-I genotyping in advanced esophageal squamous cell carcinoma patients receiving immune checkpoint inhibitor monotherapy.
Wang L; Zhu Y; Zhang B; Wang X; Mo H; Jiao Y; Xu J; Huang J
Thorac Cancer; 2022 Jun; 13(11):1631-1641. PubMed ID: 35437954
[TBL] [Abstract][Full Text] [Related]
15. Circulating L-arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors.
Peyraud F; Guégan JP; Bodet D; Nafia I; Fontan L; Auzanneau C; Cousin S; Roubaud G; Cabart M; Chomy F; Le Loarer F; Chaput N; Danlos FX; Planchard D; Even C; Khettab M; Tselikas L; Besse B; Barlesi F; Soria JC; Marabelle A; Bessede A; Italiano A
Ann Oncol; 2022 Oct; 33(10):1041-1051. PubMed ID: 35850444
[TBL] [Abstract][Full Text] [Related]
16. Prognostic nutritional index predicts the prognosis of patients with advanced esophageal cancer treated with immune checkpoint inhibitors: a retrospective cohort study.
Wu M; Zhu Y; Chen X; Wang X; Lin X; Yan X; Mo P; Ye Y; Zeng Y; Yang Y; Fu Z
J Gastrointest Oncol; 2023 Feb; 14(1):54-63. PubMed ID: 36915449
[TBL] [Abstract][Full Text] [Related]
17. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
18. Dynamics of Serum Tumor Markers Can Serve as a Prognostic Biomarker for Chinese Advanced Non-small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors.
Zhang Z; Yuan F; Chen R; Li Y; Ma J; Yan X; Wang L; Zhang F; Tao H; Guo D; Huang Z; Zhang S; Li X; Zhi X; Ge X; Hu Y; Wang J
Front Immunol; 2020; 11():1173. PubMed ID: 32587591
[No Abstract] [Full Text] [Related]
19. Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients.
Mazzaschi G; Minari R; Zecca A; Cavazzoni A; Ferri V; Mori C; Squadrilli A; Bordi P; Buti S; Bersanelli M; Leonetti A; Cosenza A; Ferri L; Rapacchi E; Missale G; Petronini PG; Quaini F; Tiseo M
Lung Cancer; 2020 Oct; 148():1-11. PubMed ID: 32768804
[TBL] [Abstract][Full Text] [Related]
20. Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer.
Wang Z; Zhang Q; Qi C; Bai Y; Zhao F; Chen H; Li Z; Wang X; Chen M; Gong J; Peng Z; Zhang X; Cai J; Chen S; Zhao X; Shen L; Li J
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35705314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
